DSRV.io · Enforcement-informed quality intelligence
DSRVDSRV.io
Browse by regulation2 articles · 2 moderate

ICH Q12

Every DSRV article whose Regulatory Snapshot cites ICH Q12: the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.

Inspection exposure across the set
In brief
What has FDA cited under ICH Q12?
2 DSRV articles cite ICH Q12. Enforcement cases behind them: FDA draft guidance for industry, Q1 Stability Testing of Drug Substances and Drug Products, published for U.S. comment in June 2025 under Docket FDA-2025-D-1106, consolidating the ICH Q1A-F and Q5C stability guidelines; ICH Q14 / Q2(R2) - Analytical Procedure Development, adopted October 2023. Inspection exposure across them: 2 moderate.
What does DSRV recommend for ICH Q12?
From the newest article (Your Stability Program Was Built for a Guideline Stack FDA Is Replacing): The right response to a draft-not-for-implementation label is a controlled gap assessment against Sections 3, 7, 13, and 15, not blind SOP revision, because teams that map the direction of travel early avoid retrofitting under pressure at final regional implementation. DSRV is decision support, not legal advice; verify against the official source each article names.
  1. 5 min readModerate exposurecited as a tag

    Your Stability Program Was Built for a Guideline Stack FDA Is Replacing

    FDA's June 2025 draft ICH Q1 guidance consolidates the Q1A-F and Q5C stability guideline stack. It is still draft and not for implementation, but it signals where global stability expectations are moving.

    Case
    FDA draft guidance for industry, Q1 Stability Testing of Drug Substances and Drug Products, published for U.S. comment in June 2025 under Docket FDA-2025-D-1106, consolidating the ICH Q1A-F and Q5C stability guidelines.
    DSRV take
    The right response to a draft-not-for-implementation label is a controlled gap assessment against Sections 3, 7, 13, and 15, not blind SOP revision, because teams that map the direction of travel early avoid retrofitting under pressure at final regional implementation.
  2. 8 min readModerate exposurecited as a tag

    ICH Q14 Analytical Procedure Development: What QA Teams Need to Know

    ICH Q14 introduces a structured, science-based approach to analytical procedure development. We break down the key concepts, lifecycle management requirements, and how they align with existing Q2 and Q12 guidelines.

    Case
    ICH Q14 / Q2(R2) - Analytical Procedure Development, adopted October 2023.
    DSRV take
    Defining purpose before method - and documenting the operable design region - is what makes a method change defensible rather than a deviation.
Address this risk

Pressure-test your evidence before an inspector reads it

Bring the document that has to hold up under ICH Q12. DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.

Apply for the Stability Pilot Ask The Vault about ICH Q12

Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.